Lawrence Corey

May 17, 2024 | onlinelibrary.wiley.com | Huub C Gelderblom |Lawrence Corey |Dan Barouch

The number of new HIV acquisitions globally has declined, but not rapidly enough to meet the 2030 targets set by UNAIDS and the United Nations Sustainable Development Goals (SDGs) [1, 2]. Despite intense efforts such as those to support the UNAIDS 95-95-95 targets and to expand the availability of oral pre-exposure prophylaxis (PrEP), progress in primary prevention of HIV acquisition has lagged.

Mar 11, 2024 | nature.com | Craig A Magaret |Allan C. deCamp |Morgane Rolland |Michal Juraska |Brian Williamson |James Ludwig | +23 more

AbstractIn the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs.

Aug 17, 2023 | insights.bio | Lawrence Corey

Vaccine Insights 2023; 2(7), 283–286 10.18609/vac.2023.041 Lawrence Corey Please enter your email to access content